| ￥3200 | |
| Z05874-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 38.2 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 50-55 kDa based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of TGFBR1, mFc Chimera, Avi, Human is greater than 95% as determined by SEC-HPLC. »
TGFBR1, mFc Chimera, Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | transforming growth factor beta receptor 1 (TGFBR1), a key stimulator of tumor proliferation and metastasis, was a direct target of miR‑98‑5p. miR‑98‑5p overexpression resulted in the downregulation of TGFBR1 and the suppression of the viability, proliferation, migration and invasion of A549 and H1299 cells. |
| Synonyms | AAT5; ACVRLK4; ALK-5; ALK5; LDS1A; LDS2A; SKR4; tbetaR-I; TGFB1R1; TGF-beta RI; TGFbetaRI; TGFBR1; TGF-bRI; TGFR-1; tβR-I; TGF-β RI; TGFβRI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
